The Present and Future
State-of-the-Art Review
Management of Pulmonary Arterial Hypertension

https://doi.org/10.1016/j.jacc.2015.03.540Get rights and content
Under an Elsevier user license
open archive

Abstract

Pulmonary hypertension (PH) is common and may result from a number of disorders, including left heart disease, lung disease, and chronic thromboembolic disease. Pulmonary arterial hypertension (PAH) is an uncommon disease characterized by progressive remodeling of the distal pulmonary arteries, resulting in elevated pulmonary vascular resistance and, eventually, in right ventricular failure. Over the past decades, knowledge of the basic pathobiology of PAH and its natural history, prognostic indicators, and therapeutic options has exploded. A thorough evaluation of a patient is critical to correctly characterize the PH. Cardiac studies, including echocardiography and right heart catheterization, are key elements in the assessment. Given the multitude of treatment options currently available for PAH, assessment of risk and response to therapy is critical in long-term management. This review also underscores unique situations, including perioperative management, intensive care unit management, and pregnancy, and highlights the importance of collaborative care of the PAH patient through a multidisciplinary approach.

Key Words

echocardiography
endothelin receptor antagonists
hemodynamics
phosphodiesterase type 5 inhibitors
prostacyclins
pulmonary arterial hypertension

Abbreviations and Acronyms

CHD
congenital heart disease
CTD
connective tissue disease
IPAH
idiopathic pulmonary hypertension
mPAP
mean pulmonary artery pressure
PAH
pulmonary arterial hypertension
PCWP
pulmonary capillary wedge pressure
PH
pulmonary hypertension
PVR
pulmonary vascular resistance
RV
right ventricle/ventricular

Cited by (0)

Dr. McLaughlin has been a consultant for Actelion Bayer, Gilead, and United Therapeutics; has received research funding for clinical trials to the University of Michigan from Actelion, Bayer, Gilead, and the National Institutes of Health (R24 HL123767); and has a relationship with United Therapeutics. Dr. Shah has received research grant support from the National Institutes of Health (R01 HL107577) and Actelion Pharmaceuticals; has received generous funding from Jo Anne and Stephen A. Schiller in support of pulmonary hypertension research; has received consulting fees from the American Board of Internal Medicine, Novartis, Bayer, DC Devices, AstraZeneca, and Alnylam Pharmaceuticals; and has received speaker fees from the Pulmonary Hypertension Association and the American Society of Echocardiography. Dr. Souza has received lecture fees from Actelion, Bayer, GlaxoSmithKline, and Bristol-Myers Squibb; and has received advisory board fees from Actelion and Bayer. Dr. Humbert has served as a consultant for Actelion, Bayer, GlaxoSmithKline, and Pfizer.

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.

You can also listen to this issue's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.